Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance

Pharmacogenetics and Genomics

Volumn 16, Issue 6, 2006, Pages 439-450

  Leschziner, Guy ^a,b   Zabaneh, Delilah ^a   Pirmohamed, M ^c   Owen, Andrew ^c   Rogers, Jane ^b   Coffey, Alison J ^b   Balding, David J ^a   Bentley, David B ^b   Johnson, Michael R ^a,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

ABC transporter genes; ABCB1; MDR1; Multidrug resistance; Tagging SNPs

Indexed keywords

ABC TRANSPORTER; GEMCITABINE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ABCB4 GENE; ABCC1 GENE; ABCC2 GENE; ABCC5 GENE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DATA BASE; DRUG TRANSPORT; EXON; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE STRUCTURE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; DRUG RESISTANCE, MULTIPLE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MODELS, GENETIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

EID: 33744501248     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000197467.21964.67     Document Type: Article

References (63)

1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22:7468-7485.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-162.
3. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the human 'MDR1' gene confers resistance to colchicines, doxorubicin and vinblastine. Proc Natl Acad Sci U S A 1987; 84:3004-3008.
4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47:381-389.
5. Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, Prins JM. P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48:1073-1081.
6. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia, 2005; 46:858-877.
7. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301:7-14.
8. van speren J, Mayer U, van Tellingen O, Beijnen JH. The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 1997; 86:881-884.
9. Potschka H, Federowitz M, Loscher W. P-glycoprotein and multidrug resistance associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001; 12: 3557-3560.
10. Potschka H, Federowitz M, Loscher W. P-glycoprotein-mediated efflux of Phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327:173-176.
11. Potschka H, Federowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic activity. J Pharmacol Exp Ther 2003; 306:124-131.
12. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997; 94:4028-4033.
13. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36:1-6.
14. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001; 42:1501-1506.
15. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, van Vliet EA, et al. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004; 45:441-451.
16. Sisodiya SM, Lin WR, Squier MV, Thom V. Multidrug resistance protein 1 in focal cortical dysplasia. Lancet 2001; 357:42-43.
17. Volk HA, Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005; 128:1358-1368.
18. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
19. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13:1847-1854.
20. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-298.
21. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003; 348:1442-1448.
22. Zimprich F, SunderPlassmann R, Stogmann E, Gleiss A, DalBianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004; 63:1087-1089.
23. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in paediatric heart transplant patients. Hum Immunol 2002; 63:765-770.
24. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in paediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003; 3:477-483.
25. Zheng H, Schuetz E, Zeevi A, Zhang J, McCurry K, Webber S, et al. Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol 2005; 45:404-410.
26. Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med 2003; 136:183-185.
27. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, et al. An MDR -3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005; 19:371-380.
28. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
29. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears D, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63:1090-1092.
30. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic treatment. Epilepsia 2005; 46:643-647.
31. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258:1650-1654.
32. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54:5902-5910.
33. vanBrussel JP, Oomen MA, Vossebeld PJ, Wiemer EA, Sonneveld P, Mickisch GH. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine. BJU Int 2004; 93:1333-1338.
34. Depeille P, Cuq P, Mary S, Passagne I, Evrard A, Cupissol D, Vian L. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 2004; 64:897-905.
35. Benyahia B, Huguet S, Decleves X, Mokhtari K, Criniere E, Bernaudin JF, et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 2004; 66:65-70.
36. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, Cole SP. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002; 12:321-330.
37. Dallas S, Ronaldson PT, Bendayan M, Bendayan R. Multidrug resistance protein 1 -mediated transport of saquinavir by microglia. Neuroreport 2004; 15:1183-1186.
38. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50:583-588.
39. Matsumoto Y, Tamiya T, Nagao S. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2. J Med Invest 2005; 52:41-48.
40. Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1 - 1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 2004; 308:260-267.
41. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003; 121:172-176.
42. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005; 4:855-863.
43. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000; 97:7476-7481.
44. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301.
45. Zhao Z, Sheps JA, Ling V, Fang LL, Baillie DL. Expression analysis of ABC transporters reveals differential functions of tandemly duplicated genes in Caenorhabditis elegans. J Mol Biol 2004; 344:409-417.
46. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, Styles JA, et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 2001; 20:1300-1306.
47. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004; 3:833-838.
48. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
49. Barrett JC, Fry B, Mailer J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
50. Pritchard JK, Stephens M, Donnelly R Inference of population structure using multilocus genotype data. Genetics 2000; 155:945-959.
51. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus data: linked loci and correlated allele frequencies. Genetics 2003; 164:1567-1587.
52. Crawford D, Bhangale T, Li N, Rieder M, Nickerson D, Stephens M. Evidence for substantial fine-scale variation in recombination rates across the human genome. Nat Genet 2004; 36:700-706.
53. Stephens M, Smith N, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
54. Li N, Stephens M. Modelling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data. Genetics 2003; 165:2213-2233.
55. Kroetz DL, PauliMagnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-494.
56. Maniatis N, Collins A, Xu CF, McCarthy LC, Hewett DR, Tapper W, et al. The first linkage disequilibrium (LD) maps: delineation of hot and cold blocks by diplotype analysis. Proc Natl Acad Sci U S A 2002; 99:2228-2233.
57. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
58. Illmer T, Schuler US, Thiede C, Schwartz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukaemia. Cancer Res 2002; 62:4955-4962.
59. Moriya Y, Nakamura, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2001; 25:1356-1359.
60. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwartz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
61. Kurata Y, Ieiri I, Kimura M, MoritaT, Irie S, Urae A, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.
62. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72:572-583.
63. Grant CE, Kurz EU, Cole SPC, Deeley RG. Analysis of the intron-exon organisation of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 1997; 45:368-378.